T cells and IL-17 in lupus nephritis

Clinical Immunology

Volumn 185, Issue , 2017, Pages 95-99

  Koga, Tomohiro ^a,b   Ichinose, Kunihiro ^a,b   Tsokos, George C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Interleukin 17; Lupus nephritis; Systemic lupus erythematosus; T cells

Indexed keywords

BIOLOGICAL MARKER; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IV; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; INTERLEUKIN 17; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHOPROTEIN PHOSPHATASE 2A; RHO KINASE;

ARTICLE; CYTOKINE PRODUCTION; GENE CONTROL; GLOMERULONEPHRITIS; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY;

ANIMALS; HUMANS; INTERLEUKIN-17; LUPUS NEPHRITIS; T-LYMPHOCYTES;

EID: 84964587127     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.04.010     Document Type: Article

References (81)

1. Tsokos, G.C., Systemic lupus erythematosus. N. Engl. J. Med. 365 (2011), 2110–2121.
2. Rovin, B.H., Parikh, S.V., Lupus nephritis: the evolving role of novel therapeutics. Am. J. Kidney Dis. 63 (2014), 677–690.
3. Rovin, B.H., The chemokine network in systemic lupus erythematous nephritis. Front. Biosci. 13 (2008), 904–922.
4. Jacobi, A.M., Reiter, K., Mackay, M., Aranow, C., Hiepe, F., Radbruch, A., Hansen, A., Burmester, G.R., Diamond, B., Lipsky, P.E., Dorner, T., Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum. 58 (2008), 1762–1773.
5. Clynes, R., Dumitru, C., Ravetch, J.V., Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279 (1998), 1052–1054.
6. Hedrich, C.M., Crispin, J.C., Tsokos, G.C., Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells. Autoimmunity 47 (2014), 234–241.
7. Turner, J.E., Paust, H.J., Steinmetz, O.M., Panzer, U., The Th17 immune response in renal inflammation. Kidney Int. 77 (2010), 1070–1075.
8. Borchers, A.T., Leibushor, N., Naguwa, S.M., Cheema, G.S., Shoenfeld, Y., Gershwin, M.E., Lupus nephritis: a critical review. Autoimmun. Rev. 12 (2012), 174–194.
9. Zhang, Z., Kyttaris, V.C., Tsokos, G.C., The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 183 (2009), 3160–3169.
10. Apostolidis, S.A., Crispin, J.C., Tsokos, G.C., IL-17-producing T cells in lupus nephritis. Lupus 20 (2011), 120–124.
11. Weening, J.J., D'Agati, V.D., Schwartz, M.M., Seshan, S.V., Alpers, C.E., Appel, G.B., Balow, J.E., Bruijn, J.A., Cook, T., Ferrario, F., Fogo, A.B., Ginzler, E.M., Hebert, L., Hill, G., Hill, P., Jennette, J.C., Kong, N.C., Lesavre, P., Lockshin, M., Looi, L.M., Makino, H., Moura, L.A., Nagata, M., The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15 (2004), 241–250.
12. Hahn, B.H., McMahon, M.A., Wilkinson, A., Wallace, W.D., Daikh, D.I., Fitzgerald, J.D., Karpouzas, G.A., Merrill, J.T., Wallace, D.J., Yazdany, J., Ramsey-Goldman, R., Singh, K., Khalighi, M., Choi, S.I., Gogia, M., Kafaja, S., Kamgar, M., Lau, C., Martin, W.J., Parikh, S., Peng, J., Rastogi, A., Chen, W., Grossman, J.M., American College of Rheumatology, American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 64 (2012), 797–808.
13. Bertsias, G.K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J.H., Boletis, J., Cervera, R., Dorner, T., Doria, A., Ferrario, F., Floege, J., Houssiau, F.A., Ioannidis, J.P., Isenberg, D.A., Kallenberg, C.G., Lightstone, L., Marks, S.D., Martini, A., Moroni, G., Neumann, I., Praga, M., Schneider, M., Starra, A., Tesar, V., Vasconcelos, C., van Vollenhoven, R.F., Zakharova, H., Haubitz, M., Gordon, C., Jayne, D., Boumpas, D.T., R. European League Against, D. European Renal Association-European, A. Transplant, Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis. 71 (2012), 1771–1782.
14. Konya, C., Paz, Z., Tsokos, G.C., The role of T cells in systemic lupus erythematosus: an update. Curr. Opin. Rheumatol. 26 (2014), 493–501.
15. Kyttaris, V.C., Tsokos, G.C., Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus. Curr. Opin. Rheumatol. 23 (2011), 449–453.
16. Wofsy, D., Ledbetter, J.A., Hendler, P.L., Seaman, W.E., Treatment of murine lupus with monoclonal anti-T cell antibody. J. Immunol. 134 (1985), 852–857.
17. Schiffer, L., Sinha, J., Wang, X., Huang, W., von Gersdorff, G., Schiffer, M., Madaio, M.P., Davidson, A., Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J. Immunol. 171 (2003), 489–497.
18. Valencia, X., Yarboro, C., Illei, G., Lipsky, P.E., Deficient CD4 + CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 178 (2007), 2579–2588.
19. Barath, S., Aleksza, M., Tarr, T., Sipka, S., Szegedi, G., Kiss, E., Measurement of natural (CD4 + CD25high) and inducible (CD4 + IL-10 +) regulatory T cells in patients with systemic lupus erythematosus. Lupus 16 (2007), 489–496.
20. Yan, B., Ye, S., Chen, G., Kuang, M., Shen, N., Chen, S., Dysfunctional CD4 +,CD25 + regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum. 58 (2008), 801–812.
21. Laurence, A., Tato, C.M., Davidson, T.S., Kanno, Y., Chen, Z., Yao, Z., Blank, R.B., Meylan, F., Siegel, R., Hennighausen, L., Shevach, E.M., O'Shea, J., Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26 (2007), 371–381.
22. Yang, X.P., Ghoreschi, K., Steward-Tharp, S.M., Rodriguez-Canales, J., Zhu, J., Grainger, J.R., Hirahara, K., Sun, H.W., Wei, L., Vahedi, G., Kanno, Y., O'Shea, J.J., Laurence, A., Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 12 (2011), 247–254.
23. Gomez-Martin, D., Diaz-Zamudio, M., Crispin, J.C., Alcocer-Varela, J., Interleukin 2 and systemic lupus erythematosus: beyond the transcriptional regulatory net abnormalities. Autoimmun. Rev. 9 (2009), 34–39.
24. Lieberman, L.A., Tsokos, G.C., The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. J. Biomed. Biotechnol., 2010, 2010, 740619.
25. Humrich, J.Y., Morbach, H., Undeutsch, R., Enghard, P., Rosenberger, S., Weigert, O., Kloke, L., Heimann, J., Gaber, T., Brandenburg, S., Scheffold, A., Huehn, J., Radbruch, A., Burmester, G.R., Riemekasten, G., Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 204–209.
26. Koga, T., Ichinose, K., Mizui, M., Crispin, J.C., Tsokos, G.C., Calcium/calmodulin-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus. J. Immunol. 189 (2012), 3490–3496.
27. Solomou, E.E., Juang, Y.T., Gourley, M.F., Kammer, G.M., Tsokos, G.C., Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol. 166 (2001), 4216–4222.
28. Tenbrock, K., Juang, Y.T., Tolnay, M., Tsokos, G.C., The cyclic adenosine 5′-monophosphate response element modulator suppresses IL-2 production in stimulated T cells by a chromatin-dependent mechanism. J. Immunol. 170 (2003), 2971–2976.
29. Wong, H.K., Kammer, G.M., Dennis, G., Tsokos, G.C., Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J. Immunol. 163 (1999), 1682–1689.
30. Kyttaris, V.C., Juang, Y.T., Tenbrock, K., Weinstein, A., Tsokos, G.C., Cyclic adenosine 5′-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J. Immunol. 173 (2004), 3557–3563.
31. Mizui, M., Koga, T., Lieberman, L.A., Beltran, J., Yoshida, N., Johnson, M.C., Tisch, R., Tsokos, G.C., IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. J. Immunol. 193 (2014), 2168–2177.
32. Ouyang, W., Kolls, J.K., Zheng, Y., The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28 (2008), 454–467.
33. Burkett, P.R., Meyer zu Horste, G., Kuchroo, V.K., Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. J. Clin. Invest. 125 (2015), 2211–2219.
34. Moulton, V.R., Tsokos, G.C., T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J. Clin. Invest. 125 (2015), 2220–2227.
35. Wong, C.K., Ho, C.Y., Li, E.K., Lam, C.W., Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 9 (2000), 589–593.
36. Wong, C.K., Lit, L.C., Tam, L.S., Li, E.K., Wong, P.T., Lam, C.W., Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin. Immunol. 127 (2008), 385–393.
37. Vincent, F.B., Northcott, M., Hoi, A., Mackay, F., Morand, E.F., Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res. Ther., 15, 2013, R97.
38. Crispin, J.C., Oukka, M., Bayliss, G., Cohen, R.A., Van Beek, C.A., Stillman, I.E., Kyttaris, V.C., Juang, Y.T., Tsokos, G.C., Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181 (2008), 8761–8766.
39. Sutton, C.E., Mielke, L.A., Mills, K.H., IL-17-producing gammadelta T cells and innate lymphoid cells. Eur. J. Immunol. 42 (2012), 2221–2231.
40. Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymour, B., Lucian, L., W. To, Kwan, S., Churakova, T., Zurawski, S., Wiekowski, M., Lira, S.A., Gorman, D., Kastelein, R.A., Sedgwick, J.D., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003), 744–748.
41. Murphy, C.A., Langrish, C.L., Chen, Y., Blumenschein, W., McClanahan, T., Kastelein, R.A., Sedgwick, J.D., Cua, D.J., Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198 (2003), 1951–1957.
42. Yen, D., Cheung, J., Scheerens, H., Poulet, F., McClanahan, T., McKenzie, B., Kleinschek, M.A., Owyang, A., Mattson, J., Blumenschein, W., Murphy, E., Sathe, M., Cua, D.J., Kastelein, R.A., Rennick, D., IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116 (2006), 1310–1316.
43. Duerr, R.H., Taylor, K.D., Brant, S.R., Rioux, J.D., Silverberg, M.S., Daly, M.J., Steinhart, A.H., Abraham, C., Regueiro, M., Griffiths, A., Dassopoulos, T., Bitton, A., Yang, H., Targan, S., Datta, L.W., Kistner, E.O., Schumm, L.P., Lee, A.T., Gregersen, P.K., Barmada, M.M., Rotter, J.I., Nicolae, D.L., Cho, J.H., A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006), 1461–1463.
44. Leng, R.X., Pan, H.F., Chen, G.M., Wang, C., Qin, W.Z., Chen, L.L., Tao, J.H., Ye, D.Q., IL-23: a promising therapeutic target for systemic lupus erythematosus. Arch. Med. Res. 41 (2010), 221–225.
45. Zickert, A., Amoudruz, P., Sundstrom, Y., Ronnelid, J., Malmstrom, V., Gunnarsson, I., IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol., 16, 2015, 7.
46. Rana, A., Minz, R.W., Aggarwal, R., Anand, S., Pasricha, N., Singh, S., Gene expression of cytokines (TNF-alpha, IFN-gamma), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 21 (2012), 1105–1112.
47. Kyttaris, V.C., Zhang, Z., Kuchroo, V.K., Oukka, M., Tsokos, G.C., Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J. Immunol. 184 (2010), 4605–4609.
48. Kyttaris, V.C., Kampagianni, O., Tsokos, G.C., Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice. BioMed Res. Int., 2013, 2013, 861028.
49. De Souza, A., Ali-Shaw, T., Strober, B.E., Franks, A.G. Jr., Successful treatment of subacute lupus erythematosus with ustekinumab. Arch. Dermatol. 147 (2011), 896–898.
50. Leonardi, C.L., Kimball, A.B., Papp, K.A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L.T., Gordon, K.B., P.s. investigators, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371 (2008), 1665–1674.
51. McInnes, I.B., Kavanaugh, A., Gottlieb, A.B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A.M., Doyle, M.K., Group, P.S., Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382 (2013), 780–789.
52. Kwan, B.C., Tam, L.S., Lai, K.B., Lai, F.M., Li, E.K., Wang, G., Chow, K.M., Li, P.K., Szeto, C.C., The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. Rheumatology (Oxford) 48 (2009), 1491–1497.
53. Juang, Y.T., Wang, Y., Jiang, G., Peng, H.B., Ergin, S., Finnell, M., Magilavy, A., Kyttaris, V.C., Tsokos, G.C., PP2A dephosphorylates Elf-1 and determines the expression of CD3zeta and FcRgamma in human systemic lupus erythematosus T cells. J. Immunol. 181 (2008), 3658–3664.
54. Juang, Y.T., Rauen, T., Wang, Y., Ichinose, K., Benedyk, K., Tenbrock, K., Tsokos, G.C., Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus. J. Biol. Chem. 286 (2011), 1795–1801.
55. Katsiari, C.G., Kyttaris, V.C., Juang, Y.T., Tsokos, G.C., Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J. Clin. Invest. 115 (2005), 3193–3204.
56. Sunahori, K., Juang, Y.T., Tsokos, G.C., Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac alpha promoter determines CREB binding and activity. J. Immunol. 182 (2009), 1500–1508.
57. Crispin, J.C., Apostolidis, S.A., Rosetti, F., Keszei, M., Wang, N., Terhorst, C., Mayadas, T.N., Tsokos, G.C., Cutting edge: protein phosphatase 2A confers susceptibility to autoimmune disease through an IL-17-dependent mechanism. J. Immunol. 188 (2012), 3567–3571.
58. Lee, J.H., Katakai, T., Hara, T., Gonda, H., Sugai, M., Shimizu, A., Roles of p-ERM and Rho-ROCK signaling in lymphocyte polarity and uropod formation. J. Cell Biol. 167 (2004), 327–337.
59. Li, Y., Harada, T., Juang, Y.T., Kyttaris, V.C., Wang, Y., Zidanic, M., Tung, K., Tsokos, G.C., Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J. Immunol. 178 (2007), 1938–1947.
60. Crispin, J.C., Keenan, B.T., Finnell, M.D., Bermas, B.L., Schur, P., Massarotti, E., Karlson, E.W., Fitzgerald, L.M., Ergin, S., Kyttaris, V.C., Tsokos, G.C., Costenbader, K.H., Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum. 62 (2010), 1431–1437.
61. Isgro, J., Gupta, S., Jacek, E., Pavri, T., Duculan, R., Kim, M., Kirou, K.A., Salmon, J.E., Pernis, A.B., Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus. Arthritis Rheum. 65 (2013), 1592–1602.
62. Stirzaker, R.A., Biswas, P.S., Gupta, S., Song, L., Bhagat, G., Pernis, A.B., Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. Lupus 21 (2012), 656–661.
63. Biswas, P.S., Gupta, S., Chang, E., Song, L., Stirzaker, R.A., Liao, J.K., Bhagat, G., Pernis, A.B., Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J. Clin. Invest. 120 (2010), 3280–3295.
64. Apostolidis, S.A., Rauen, T., Hedrich, C.M., Tsokos, G.C., Crispin, J.C., Protein phosphatase 2A enables expression of interleukin 17 (IL-17) through chromatin remodeling. J. Biol. Chem. 288 (2013), 26775–26784.
65. Rauen, T., Hedrich, C.M., Juang, Y.T., Tenbrock, K., Tsokos, G.C., cAMP-responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. J. Biol. Chem. 286 (2011), 43437–43446.
66. Lippe, R., Ohl, K., Varga, G., Rauen, T., Crispin, J.C., Juang, Y.T., Kuerten, S., Tacke, F., Wolf, M., Roebrock, K., Vogl, T., Verjans, E., Honke, N., Ehrchen, J., Foell, D., Skryabin, B., Wagner, N., Tsokos, G.C., Roth, J., Tenbrock, K., CREMalpha overexpression decreases IL-2 production, induces a T(H)17 phenotype and accelerates autoimmunity. J. Mol. Cell Biol. 4 (2012), 121–123.
67. Hedrich, C.M., Crispin, J.C., Rauen, T., Ioannidis, C., Apostolidis, S.A., Lo, M.S., Kyttaris, V.C., Tsokos, G.C., cAMP response element modulator alpha controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 16606–16611.
68. Hedrich, C.M., Rauen, T., Crispin, J.C., Koga, T., Ioannidis, C., Zajdel, M., Kyttaris, V.C., Tsokos, G.C., cAMP-responsive element modulator alpha (CREMalpha) trans-represses the transmembrane glycoprotein CD8 and contributes to the generation of CD3 + CD4 − CD8 − T cells in health and disease. J. Biol. Chem. 288 (2013), 31880–31887.
69. Hedrich, C.M., Crispin, J.C., Rauen, T., Ioannidis, C., Koga, T., Rodriguez Rodriguez, N., Apostolidis, S.A., Kyttaris, V.C., Tsokos, G.C., cAMP responsive element modulator (CREM) alpha mediates chromatin remodeling of CD8 during the generation of CD3 + CD4 − CD8 − T cells. J. Biol. Chem. 289 (2014), 2361–2370.
70. Racioppi, L., Means, A.R., Calcium/calmodulin-dependent kinase IV in immune and inflammatory responses: novel routes for an ancient traveller. Trends Immunol. 29 (2008), 600–607.
71. Juang, Y.T., Wang, Y., Solomou, E.E., Li, Y., Mawrin, C., Tenbrock, K., Kyttaris, V.C., Tsokos, G.C., Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J. Clin. Invest. 115 (2005), 996–1005.
72. Koga, T., Hedrich, C.M., Mizui, M., Yoshida, N., Otomo, K., Lieberman, L.A., Rauen, T., Crispin, J.C., Tsokos, G.C., CaMK4-dependent activation of AKT/mTOR and CREM-alpha underlies autoimmunity-associated Th17 imbalance. J. Clin. Invest. 124 (2014), 2234–2245.
73. Ichinose, K., Rauen, T., Juang, Y.T., Kis-Toth, K., Mizui, M., Koga, T., Tsokos, G.C., Cutting edge: calcium/calmodulin-dependent protein kinase type IV is essential for mesangial cell proliferation and lupus nephritis. J. Immunol. 187 (2011), 5500–5504.
74. Koga, T., Mizui, M., Yoshida, N., Otomo, K., Lieberman, L.A., Crispin, J.C., Tsokos, G.C., KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3(+) regulatory T cells in MRL/lpr mice. Autoimmunity 47 (2014), 445–450.
75. Koga, T., Otomo, K., Mizui, M., Yoshida, N., Umeda, M., Ichinose, K., Kawakami, A., Tsokos, G.C., CaMK4 facilitates the recruitment of IL-17-producing cells to target organs through the CCR6/CCL20 axis in Th17-driven inflammatory diseases. Arthritis Rheum., 2016.
76. Bhaskar, P.T., Hay, N., The two TORCs and Akt. Dev. Cell 12 (2007), 487–502.
77. Powell, J.D., Delgoffe, G.M., The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 33 (2010), 301–311.
78. Gentry, E.G., Henderson, B.W., Arrant, A.E., Gearing, M., Feng, Y., Riddle, N.C., Herskowitz, J.H., Rho kinase inhibition as a therapeutic for progressive supranuclear palsy and corticobasal degeneration. J. Neurosci. 36 (2016), 1316–1323.
79. Lai, Z.W., Borsuk, R., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Francis, L., Tily, H., Bartos, A., Faraone, S.V., Phillips, P., Perl, A., Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J. Immunol. 191 (2013), 2236–2246.
80. Kato, H., Perl, A., Mechanistic target of rapamycin complex 1 expands Th17 and IL-4 + CD4 − CD8 − double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J. Immunol. 192 (2014), 4134–4144.
81. Caza, T.N., Fernandez, D.R., Talaber, G., Oaks, Z., Haas, M., Madaio, M.P., Lai, Z.W., Miklossy, G., Singh, R.R., Chudakov, D.M., Malorni, W., Middleton, F., Banki, K., Perl, A., HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. Ann. Rheum. Dis. 73 (2014), 1888–1897.